Semler Scientific to Commence Trading on Nasdaq
Effective Tuesday, September 28, 2021
Sep 27, 2021, 08:03 ET
SANTA CLARA, Calif., Sept. 27, 2021 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that The Nasdaq Stock Market LLC ("Nasdaq") has approved the listing of its common stock on the exchange. Semler Scientific's common stock will begin trading on The Nasdaq Capital Market under the trading symbol "SMLR" at the open of the market on Tuesday, September 28, 2021. Semler Scientific's common stock will continue to trade on the OTCQB until market close on September 27, 2021.
"The listing of our stock on the Nasdaq is intended to enhance liquidity of our shares and to enable the expansion of our stockholder base," stated Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific.
About Semler Scientific, Inc.:
Semler Scientific, Inc. is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Semler Scientific's mission is to develop, manufacture and market innovative products and services that assist its customers in evaluating and treating chronic diseases. Semler Scientific commercially launched its first patented and U.S. Food and Drug Administration, or FDA, cleared product in 2011, and received FDA 510(k) clearance for QuantaFlo®, the next generation version of this product, in 2015. QuantaFlo® is a rapid point-of-care test that measures arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease. QuantaFlo® is used by Semler Scientific's customers to more comprehensively evaluate their patients for risk of heart attacks and strokes. Semler Scientific believes it is positioned to provide valuable information to its insurance company and physician customers, which in turn permits them to better guide patient care. Additional information about Semler Scientific can be found at semlerscientific.com.
This press release contains "forward-looking" statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "may," "will," "intend," "expect," "anticipate," "estimate," "project," "would," "could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include statements regarding the planned listing on Nasdaq and anticipated benefits thereof. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific's actual results to differ materially from those discussed here, such as whether or not insurance plans and other customers will continue to license its cardiovascular testing products, whether or not it will be able to successfully expand its product offering, whether or not it will be able to diversify its stockholder base and achieve greater liquidity on Nasdaq, as well as uncertainty created by COVID–19, along with those risk factors detailed in Semler Scientific's SEC filings. These forward-looking statements involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations, or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.
Susan A. Noonan
S.A. Noonan Communications
212 966 3650
SOURCE: Semler Scientific, Inc.
SOURCE Semler Scientific, Inc.
Share this article